Evidence map›Paper›PMID 35469070›Full record

Trial reportNature medicine2022

Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial.

Olivier Mir, Marie Ferrua, Aude Fourcade, Delphine Mathivon, Adeline Duflot-Boukobza, Sarah Dumont, Eric Baudin, Suzette Delaloge, David Malka, Laurence Albiges and 11 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02828462 (Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics), which is not on this map. Cited by 79 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 10 pooled it
13.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02828462 unknown statusnot on this map

Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics

TypeobservationalSponsorGustave Roussy, Cancer Campus, Grand ParisRan2016 to 2020Enrolled1,000ConditionsMetastatic Cancer, Hematological MalignancyArmsCAPRI
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 10 syntheses or guidelines pooled it, 133 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Effectiveness of mHealth apps on adherence and symptoms to oral anticancer medications: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability.Annals of clinical and translational neurology · 2026
    Trial
  12. Trial
  13. Trial
  14. A mobile supportive care app for patients with metastatic lung cancer: the Lung Cancer App (LuCApp) randomized controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Trial
  20. Trial

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 2 institutions in 1 country.

Olivier MirDepartment of Ambulatory Cancer Care, Gustave Roussy, Villejuif, France. olivier.mir@gustaveroussy.fr.ORCID http://orcid.org/0000-0002-6761-4002
Marie FerruaDepartment of Ambulatory Cancer Care, Gustave Roussy, Villejuif, France.
Aude FourcadeDepartment of Ambulatory Cancer Care, Gustave Roussy, Villejuif, France.
Delphine MathivonDepartment of Ambulatory Cancer Care, Gustave Roussy, Villejuif, France.
Adeline Duflot-BoukobzaDepartment of Ambulatory Cancer Care, Gustave Roussy, Villejuif, France.
Sarah DumontDivision of Cancer Medicine, Gustave Roussy, Villejuif, France.
Eric BaudinDepartment of Endocrine Oncology, Gustave Roussy, Villejuif, France.
Suzette DelalogeDivision of Cancer Medicine, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0003-2106-9165
David MalkaDivision of Cancer Medicine, Gustave Roussy, Villejuif, France.
Laurence AlbigesDivision of Cancer Medicine, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-5734-3480
Patricia PautierDivision of Cancer Medicine, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-1459-268X
Caroline RobertDivision of Cancer Medicine, Gustave Roussy, Villejuif, France.ORCID http://orcid.org/0000-0002-9493-0238
David PlanchardDivision of Cancer Medicine, Gustave Roussy, Villejuif, France.
Stéphane de BottonDivision of Hematology, Gustave Roussy, Villejuif, France.
Florian ScottéDivision of Interdisciplinary Patients Care Pathways (DIOPP), Gustave Roussy, Villejuif, France.
François LemareDepartment of Ambulatory Cancer Care, Gustave Roussy, Villejuif, France.
May AbbasDivision of Interdisciplinary Patients Care Pathways (DIOPP), Gustave Roussy, Villejuif, France.
Marilène GuilletDepartment of Ambulatory Cancer Care, Gustave Roussy, Villejuif, France.
Vanessa PuglisiDepartment of Ambulatory Cancer Care, Gustave Roussy, Villejuif, France.
Mario Di PalmaDepartment of Ambulatory Cancer Care, Gustave Roussy, Villejuif, France.
Etienne MinvielleDivision of Interdisciplinary Patients Care Pathways (DIOPP), Gustave Roussy, Villejuif, France.
Institut Gustave Roussy · FRÉcole Polytechnique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Strategies that individualize the care of cancer patients receiving oral anticancer agents offer opportunities to improve treatment adherence and patient care. However, the impact of digital remote monitoring systems in this setting has not been evaluated. Here, we report the results of a phase 3 trial (CAPRI, NCT02828462) to assess the impact of a nurse navigator-led program on treatment delivery for patients with metastatic cancer. Patients receiving approved oral anticancer agents were randomized (1:1) to an intervention combining a nurse navigator-led follow-up system and a web portal-smartphone application on top of usual care, or to usual symptom monitoring at the discretion of the treating oncologist, for a duration of 6 months. The primary objective included optimization of the treatment dose. Secondary objectives were grade ≥3 toxicities, patient experience, rates and duration of hospitalization, response and survival, and quality of life. In 559 evaluable patients the relative dose intensity was higher in the experimental arm (93.4% versus 89.4%, P = 0.04). The intervention improved the patient experience (Patient Assessment of Chronic Illness Care score, 2.94 versus 2.67, P = 0.01), reduced the days of hospitalization (2.82 versus 4.44 days, P = 0.02), and decreased treatment-related grade ≥3 toxicities (27.6% versus 36.9%, P = 0.02). These findings show that patient-centered care through remote monitoring of symptoms and treatment may improve patient outcomes and experience.

Indexed as

Antineoplastic AgentsNeoplasmsChronic DiseaseHospitalizationHumansQuality of LifeAntineoplastic Agents

Identifiers

PMID35469070
OpenAlexW4224863993

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.